Compare GSBC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSBC | REPL |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.4M | 692.8M |
| IPO Year | 1996 | 2018 |
| Metric | GSBC | REPL |
|---|---|---|
| Price | $68.15 | $5.34 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $65.00 | $5.67 |
| AVG Volume (30 Days) | 94.3K | ★ 8.1M |
| Earning Date | 04-15-2026 | 05-21-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 17.68 | 5.25 |
| EPS | ★ 1.58 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.56 | N/A |
| P/E Ratio | $43.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $53.76 | $1.50 |
| 52 Week High | $70.91 | $13.24 |
| Indicator | GSBC | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 62.53 |
| Support Level | $60.23 | $4.39 |
| Resistance Level | $70.91 | $5.84 |
| Average True Range (ATR) | 1.57 | 0.53 |
| MACD | -0.20 | 0.43 |
| Stochastic Oscillator | 44.98 | 96.61 |
Great Southern Bancorp Inc is a bank holding company. Through its subsidiaries, the company mainly offers a variety of banking and banking-related services, such as accepting deposits, granting loans and advances, offering mobile banking services, issuing debit and credit cards, safe deposit boxes, ATM facilities, and other related products and services. These services are offered through full-service retail banking offices and loan production offices located across different states in the U.S., including Missouri, Iowa, Kansas, Minnesota, Nebraska, Arkansas, and others.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.